Molecular Profiling Reveals a Tumor-Promoting Phenotype of Monocytes and Macrophages in Human Cancer Progression  by Chittezhath, Manesh et al.
Immunity
ArticleMolecular Profiling Reveals a Tumor-Promoting
Phenotype of Monocytes and Macrophages
in Human Cancer Progression
Manesh Chittezhath,1 Manprit Kaur Dhillon,1 Jyue Yuan Lim,1 Damya Laoui,2,3 Irina N. Shalova,1 Yi Ling Teo,1
Jinmiao Chen,1 Revathy Kamaraj,4 Lata Raman,4 Josephine Lum,1 Thomas Paulraj Thamboo,5 Edmund Chiong,4
Francesca Zolezzi,1 Henry Yang,1 Jo A. Van Ginderachter,2,3 Michael Poidinger,1 Alvin S.C. Wong,6
and Subhra K. Biswas1,*
1Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Biopolis, Singapore 138648, Singapore
2Laboratory of Myeloid Cell Immunology, VIB, Brussels 1050, Belgium
3Cellular and Molecular Immunology Lab, Vrije Universiteit Brussel, Brussels 1050, Belgium
4Department of Urology
5Department of Pathology
6Department of Haematology-Oncology
National University Health System, Lower Kent Ridge Road, Singapore 119074, Singapore
*Correspondence: subhra_biswas@immunol.a-star.edu.sg
http://dx.doi.org/10.1016/j.immuni.2014.09.014SUMMARY
Monocytes andmacrophages aremajor components
of the tumor microenvironment, but their contribu-
tions to human cancer are poorly understood.
We used molecular profiling combined with func-
tional assays to investigate the role of these cells in
human renal cell carcinoma (RCC). Bloodmonocytes
from RCC patients displayed a tumor-promoting
transcriptional profile that supported functions like
angiogenesis and invasion. Induction of this protu-
mor phenotype required an interleukin-1 receptor
(IL-1R)-dependent mechanism. Indeed, targeting of
IL-1-IL-1R axis in a human RCC xenograft model
abrogated the protumor phenotype of tumor-asso-
ciated macrophages (TAMs) and reduced tumor
growth in vivo. Supporting this, meta-analysis of
gene expression from human RCC tumors showed
IL1B expression to correlate with myelomonocytic
markers, protumor genes, and tumor staging.
Analyzing RCC patient tumors confirmed the protu-
mor phenotype of TAMs. These data provide direct
evidence for a tumor-promoting role of monocytes
and macrophages in human cancer and indicate IL-
1-IL-1R as a possible therapeutic target.
INTRODUCTION
The causal link between inflammation and cancer is now well
established (Coussens et al., 2013; Grivennikov et al., 2010;
Hanahan and Weinberg, 2011; Mantovani et al., 2008). Mono-
cytes and macrophages represent the major inflammatory infil-
trate associated within most solid tumors (Mantovani et al.,
2008; Noy and Pollard, 2014), and their recruitment and activa-
tion at these sites is largely regulated by tumor-derived signalsIincluding chemokines, cytokines, and endogenous signals
(Mantovani et al., 2008). The role of these cells in promoting tu-
mor progression has been revealed primarily by studies involving
their depletion or accumulation in spontaneous and transplanted
murine tumor models (Biswas and Mantovani, 2010; Biswas
et al., 2008; Coussens et al., 2000; Lin et al., 2006; Noy and
Pollard, 2014). In contrast, our knowledge of the role played by
monocytes andmacrophages in human cancers remains limited.
Most of the available human data come from epidemiological
studies that demonstrate a correlation between increased
macrophage density and poor prognosis in various cancers
(including thyroid, breast, cervix, lung, and liver) (Bingle et al.,
2002; Zhang et al., 2012) and with poor responses to chemo-
therapy (DeNardo et al., 2011). High circulatingmonocyte counts
have also been associated with poor survival in patients with
other cancers such as melanoma, head and neck cancer, and
malignant pleural mesothelioma (Burt et al., 2011). However,
an in-depth characterization of monocytes and macrophages
in human cancer together with the mechanism(s) responsible
for ‘‘educating’’ these cells to a tumor-promoting phenotype
in vivo is still lacking.
We investigated the role played by monocytes and macro-
phages in human renal cell carcinoma (RCC), which is the
most common type of kidney cancer in humans and the third
most common urological cancer after prostate and bladder can-
cer. The incidence of RCC has steadily increased over the last 20
years, leading to estimates that approximately 58,240 patients
will have been diagnosed by the start of this decade, with
13,040 cases presenting in the United States alone (Chow
et al., 2010; Howlader et al., 2000). RCC is characterized by a
lack of early warning symptoms, a variety of clinical manifesta-
tions, resistance to chemo- and radiation therapy, and most
importantly, a high rate of metastasis (Koul et al., 2011). Indeed,
around 50% of RCC patients with localized disease subse-
quently develop metastatic disease, and the 5-year survival for
metastatic disease is only 9%. Although targeted antiangiogenic
agents in the form of mammalian target of rapamycin (mTOR) in-
hibitors, tyrosine kinase inhibitors, and monoclonal antibodiesmmunity 41, 815–829, November 20, 2014 ª2014 Elsevier Inc. 815
AC
D E
B Figure 1. RCC Monocytes Exhibit a Distinct
Transcriptome Profile
(A) Principal component analysis (PCA) performed
on the monocyte versus RCC monocyte tran-
scriptome. Figure shows scatter plot of the 1st
(PCA1) versus 2nd (PCA2) principal components;
PC1 and PC2 account for 67% and 10% of the
variance in the data, respectively. Dots corre-
sponds to the number of patients or healthy
subjects used in the transcriptome study (four per
group).
(B) Hierarchical clustering with Pearson’s correla-
tion and complete linkage of monocyte and RCC-
monocyte samples. The samples were subjected
to multiscale bootstrap resampling, all branches
had a confidence of 100% over 1,000 replicates.
(C) Gene Ontology (GO) analysis of differentially
modulated genes classified by their biological
functions and arranged according to their statisti-
cal significance (p value indicated on x axis) from
DAVID.
(D) Heatmap showing differential expression of
indicated genes in RCC monocytes as compared
to monocytes. DEGs determined by Limma, and
row-based Z score normalized. Cancer staging for
RCC samples is also indicated.
(E) Bar graph showing differentially expressed
M1- and M2-specific genes in RCC monocytes as
compared to monocytes. See also Figure S1 and
Table S1.
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Role of Monocytes and Macrophages in Human Cancerare increasingly being used (Motzer et al., 2007a, 2007b) and
have delivered improvements in progression-free survival, RCC
still remains a challenging disease to treat. A better understand-
ing of the cellular and molecular interactions that contribute to
RCC progression is therefore necessary to support the future
development of more effective therapeutic strategies.
The present study reports a tumor-promoting role for mono-
cytes and macrophages in human RCC and identifies a molecu-
lar mechanism responsible for polarizing these cells toward a
protumor phenotype. We further demonstrate that in vitro and
in vivo targeting of this mechanism not only prevents monocytes
and macrophages from adopting a protumor phenotype but also
favors the acquisition of an antitumor phenotype, resulting in
decreased tumor growth in a xenograft model of human RCC.
These findings define a critical component of tumor progression816 Immunity 41, 815–829, November 20, 2014 ª2014 Elsevier Inc.in human RCC and identify a potential
target pathway for future therapeutic
interventions.
RESULTS
Blood Monocytes from RCC
Patients Exhibit a Distinct
Transcriptomal Profile
In order to clarify the role played
by monocytes in human RCC progres-
sion, we first performed transcriptomal
profiling of these cells in RCC patients.
Blood monocytes from RCC patients
(RCC monocytes) and healthy donors(monocytes)were isolated andcomparedbymicroarray analysis,
using the 48K genome-wide human Illumina HT-12v4 microarray
(as described in the Supplemental Experimental Procedures
section and shown in Figure S1A available online). Principal
component analysis (PCA) and hierarchical clustering clearly
segregated themonocyte trancriptomeprofile of healthy controls
from that of RCC patients, suggesting the populations to be
transcriptomally distinct (Figures 1A and 1B). Limmadifferentially
expressed gene (DEG) analysis of the transcriptome revealed
differential modulation of 2,384 genes (1,054 upregulated;
1,330 downregulated; FDR < 0.05) in RCCmonocytes compared
with control monocytes (Figure S1B). These DEGs were then
grouped using gene ontology (GO) biological processes, which
identified immune-related genes as the most significant upregu-
lated gene function group in RCC monocytes (Figure 1C).
Table 1. Upregulation of Selected Inflammatory and Protumor Genes in RCC Monocytesa
Gene Symbol Full Name Fold change (Log 2)
Inflammatory cytokine/chemokine genes
CCL3 Homo sapiens chemokine (C-C motif) ligand 3 (CCL3), mRNA. 2.43
CCL3L1 Homo sapiens chemokine (C-C motif) ligand 3-like 1 (CCL3L1), mRNA. 2.39
CCL4L2 Homo sapiens chemokine (C-C motif) ligand 4-like 2 (CCL4L2), mRNA. 3.16
CCL5 Homo sapiens chemokine (C-C motif) ligand 5 (CCL5), mRNA. 2.14
CCL7 Homo sapiens chemokine (C-C motif) ligand 7 (CCL7), mRNA. 3.16
CCL20 Homo sapiens chemokine (C-C motif) ligand 20 (CCL20), mRNA. 4.05
CXCL2 Homo sapiens chemokine (C-X-C motif) ligand 2 (CXCL2), mRNA. 3.11
TNF Homo sapiens tumor necrosis factor (TNF superfamily, member 2) (TNF), mRNA. 2.83
IL1A Homo sapiens interleukin 1, alpha (IL-1A), mRNA. 2.65
IL1B Homo sapiens interleukin 1, beta (IL-1B), mRNA. 3.48
IL24 Homo sapiens interleukin 24 (IL-24), transcript variant 2, mRNA. 1.55
Protumoral genes
IL8 Homo sapiens interleukin 8 (IL-8), mRNA. 1.58
VEGFA Homo sapiens vascular endothelial growth factor A (VEGFA), transcript variant 2, mRNA. 1.28
PTGS2 Homo sapiens prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and
cyclooxygenase) (PTGS2), mRNA.
3.44
MMP10 Homo sapiens matrix metallopeptidase 10 (stromelysin 2) (MMP10), mRNA. 1.86
MMP19 Homo sapiens matrix metallopeptidase 19 (MMP19), transcript variant 1, mRNA. 1.70
CXCR4 Homo sapiens chemokine (C-X-C motif) receptor 4 (CXCR4), transcript variant 1, mRNA. 2.05
HIF1A Homo sapiens hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription
factor) (HIF1A), transcript variant 2, mRNA.
1.18
aAll genes shown here are DEGs derived from the transcriptome analysis of RCC monocytes versus monocytes, as described in the Supplemental
Experimental Procedures and Results sections. Upregulated DEGs are defined by an adjusted p value% 0.05 and an absolute log2 fold change > = 1
(i.e., an absolute fold change > = 2) See also Table S1.
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Role of Monocytes and Macrophages in Human CancerWe initially focused on the expression of immune-related
genes that encode cytokines, chemokines, and growth factors
because these are known to shape the tumor microenvironment
(Biswas et al., 2008; Lewis and Pollard, 2006; Mantovani
et al., 2008). As indicated in Table 1, RCC monocytes consis-
tently displayed upregulation of a large number of proinflamma-
tory cytokine and chemokine genes (e.g., TNF, IL1A, IL1B,
IL24, CCL3, CCL3L1, CCL5, CCL7, CCL20) relative to mono-
cytes obtained from healthy controls. Importantly, RCC mono-
cytes also exhibited upregulation of several ‘‘protumor’’ genes
including PTGS2 (encoding COX2), IL8, VEGFA, MMP19,
MMP10, CXCR4, and HIF1A, which are known to mediate key
processes in tumor development (Table 1; Mantovani et al.,
2008; Murdoch et al., 2008). Figure 1D shows a heatmap repre-
sentation of selected proinflammatory and protumor genes that
were differentially expressed in RCC monocytes compared with
healthy control monocytes.
Because the tumor microenvironment can polarize myelomo-
nocytic cells (Biswas and Mantovani, 2010), we next aimed to
determine whether the gene-expression profile of RCC mono-
cytes was indicative of their polarization status. RCCmonocytes
were screened for the differential expression of a panel of M1- or
M2-polarization related genes (Martinez et al., 2006, 2013; Mur-
ray et al., 2014). The profiling data for these genes indicated that
RCC monocytes express a mixture of both M1 and M2 genes
rather than exhibiting a distinct M1 or M2 phenotype (Figure 1E).
Taken together, the transcriptome data indicated that RCC
monocytes possess a distinct gene expression profile sugges-Itive of altered function in human cancer. We therefore sought
to further validate these data and to functionally characterize
RCC monocytes in subsequent experiments. A complete list of
the DEGs can be found in Table S1 available online.
RCC Patient Monocytes Display a Proinflammatory and
Tumor-Promoting Phenotype
To further validate the gene-expression profile of RCC mono-
cytes, a panel of differentially modulated genes was chosen
from Table 1 and assessed by quantitative PCR (qPCR). qPCR
analysis confirmed significant increase in the expression
of proinflammatory cytokine and chemokine genes TNF, IL1A,
IL1B, CCL3, CCL5, CCL20, and IL6 in RCC monocytes
compared with monocytes from healthy controls (Figure 2A).
Accordingly, we were able to confirm the upregulated expres-
sion of TNF-a, IL-1b, IL-6, and CCL3 proteins in RCC monocyte
culture supernatants (Figure 2B). Further confirmation of the
microarray data was achieved by qPCR validation of the upre-
gulated expression of protumor genes IL8, VEGFA, PTGS2,
CXCR4, and MMP10 in RCC monocytes compared with control
monocytes (Figure 2C). Consistent with these data, elevated
protein expression of proangiogenic factors VEGFA and IL-8
were also detected in RCC monocyte culture supernatants as
compared with control monocytes (Figure 2D).
These data indicated that RCC monocytes upregulate
key protumor genes and proteins that have been reported to
support angiogenesis and metastasis (Murdoch et al., 2008).
To test whether RCC monocytes could actually promote suchmmunity 41, 815–829, November 20, 2014 ª2014 Elsevier Inc. 817
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Figure 2. RCC Monocytes Exhibit a Proinflammatory and Tumor-Promoting Phenotype
(A) qPCR showing expression of proinflammatory cytokine and chemokine genes in RCCmonocytes. Gene names indicated on the x axis. Data are mean ± SEM
(healthy: n = 4–6 and patient: n = 7–9).
(B) Amount of indicated cytokines and chemokines detected in the cell-free culture supernatant of RCC monocytes versus monocytes. Data are mean ± SEM
(n = 3–4).
(C) qPCR analysis of protumor gene expression in RCC monocytes. Data are mean ± SEM (healthy: n = 4–6 and patient: n = 9).
(D) Amount of proangiogenic factors detected in the culture supernatant of RCC monocytes versus monocytes. Data are mean ± SEM (n = 3).
(E) Angiogenesis assay showing endothelial tube formation on matrix gel induced by RCC monocytes. Left panel shows quantitative analysis of tube formation
(n = 3). Right panel shows inhibition of tube formation by a-VEGFR. Quantitation and bright field image of tube formation from one experiment is shown. Data are
mean ± SEM.
(F) RCC monocytes enhance the invasion of tumor cells in an in vitro invasion assay. Left panel shows quantitative analysis of tumor cell invasion (n = 2). Right
panel shows inhibition of tumor cell invasion by MMP inhibitor. Quantitation and bright field image of tumor cell invasion from one experiment is shown. Data are
mean ± SEM. Optical density is shown as a measure of amount of invaded cells. (E and F) #p < 0.05, versus RCC-Mo+a-control/vehicle. In all panels, *p < 0.05,
versus Mo.
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Role of Monocytes and Macrophages in Human Cancertumor-promoting functions, in vitro functional assays for angio-
genesis and invasion were performed. RCC monocyte super-
natant markedly enhanced tube formation by HUVEC cells
(a measure of angiogenesis) as compared to control monocyte
supernatant, indicating their proangiogenic property (Figure 2E,
left). This effect was inhibited by adding an a-VEGFR2 antibody
indicating that the proangiogenic ability of RCC monocytes was
dependent on VEGF (Figure 2E, right), consistent with the upre-
gulation of VEGFA by RCC monocytes (Figures 2C and 2D).
Additionally, data from an in vitro invasion assay using matrix-
gel-coated transwells revealed a significant increase in invasion
by RCC cells in the presence of RCC monocyte supernatant
(compared with control monocyte supernatant), suggesting
that RCC monocytes are also capable of enhancing tumor cell
invasion (Figure 2F, left). This effect was abrogated by adding
a matrix metalloproteinases (MMP) inhibitor, indicating that the
ability of RCC monocytes to promote tumor cell invasion was
dependent on MMP (Figure 2F, right), which is consistent with
the upregulation of MMP10 by RCC monocytes (Figure 2C).
Collectively, these gene-expression, protein, and in vitro func-
tional data strongly suggested that RCC monocytes exhibit an
inflammatory, protumor phenotype with potential to promote
cancer progression.
Protumor Phenotype of RCCMonocytes Is Regulated by
a Nuclear Factor-kB-MyD88 Pathway
We next sought to determine the molecular mechanism(s)
that support monocytes acquisition of a protumor phenotype.
Because NF-kB is a master regulator of many genes known
to modulate tumor development, e.g., TNFA, IL6, VEGFA,
PTGS2, andMMP (hereafter termed ‘‘protumor genes’’) (Biswas
and Lewis, 2010; Karin and Greten, 2005), we began by investi-
gating whether NF-kB activation was responsible for inducing
a protumor phenotype in RCC monocytes. In order to achieve
this, we first generated ‘‘tumor-conditioned’’ monocytes by co-
culturing monocytes obtained from healthy donors with a RCC
tumor cell line (RCC4) in a transwell plate. After 48 hr coculture,
RCC-conditioned monocytes exhibited marked increase in the
expression of protumor genes, angiogenic activity, and invasive
function compared with unconditioned monocytes (Figures
S2A–S2C). Similar results were obtained for monocytes cocul-
tured with another RCC cell line (Caki-2) (Figure S2D). These
data indicate that RCC cells can ‘‘condition’’ normal monocytes
to adopt a protumor phenotype similar to that observed in
RCC patients and could therefore be used to probe the mecha-
nisms that support monocyte acquisition of tumor-promoting
functions.
RCC-conditioned monocytes displayed evidence of NF-kB
activation as indicated by enhanced I-kBa phosphorylation
and nuclear translocation of p65 NF-kB (Figures 3A and 3B).
The role of NF-kB activation in RCC-conditioned monocytes
was further investigated using a specific inhibitory peptide for
the NF-kB regulator, IKKg. RCC-conditioned monocytes treated
with the inhibitory peptide displayed a marked decrease in
protumor genes TNF, IL6, VEGFA, and PTGS2 expression
compared with conditioned monocytes that received a control
peptide (Figure 3C). Functionally, these inhibitor-treated cells
also showed marked downregulation of angiogenic activity and
invasive behavior (Figures 3D and 3E). Together, these resultsIsuggest that the protumor phenotype of RCC-conditioned
monocytes is regulated by NF-kB activation.
We further analyzed whether the protumor phenotype of RCC-
conditioned monocytes relied on the MyD88 signaling pathway,
upstream of NF-kB. RCC-conditioned monocytes exposed to a
MyD88 inhibitory peptide displayed a marked decrease in the
expression of TNF, PTGS2, IL6, and VEGFA compared with
monocytes exposed to the control peptide (Figure 3F). Function-
ally, RCC-conditionedmonocyteswere impaired in their ability to
stimulate angiogenesis and tumor cell invasion in vitro after treat-
ment with the MyD88 inhibitory peptide (Figures 3G and 3H).
Collectively, these observations support the involvement of the
MyD88 signaling pathway in driving the protumor phenotype of
RCC-conditioned monocytes.
IL-1-IL-1R Signaling Shapes the Protumor Phenotype of
RCC Monocytes
Elevated IL-1b expression was detected in the plasma of
RCC patients (Figure S3A). Because IL-1 signals through the
MyD88-NF-kB pathway (Biswas and Lewis, 2010) and could
induce protumor genes (Figure S3B), we focused subsequent
studies on investigating the involvement of IL-1-IL-1R in medi-
ating the protumor phenotype of monocytes.
In order to assess the role of IL-1-IL-1R in inducing protumor
gene expression by RCC-conditioned monocytes, we supple-
mented Monocyte:RCC cocultures with human recombinant
IL-1 receptor antagonist (IL-1RA), to inhibit IL-1-IL-1R signaling.
IL-1RA treatment significantly inhibited the expression of protu-
mor genes in RCC-conditioned monocytes (Figure 4A). Because
TNF is another primary cytokine that is implicated in RCC
(Chuang et al., 2008), we checked in parallel the effect of adding
TNF neutralizing antibody in addition to IL-1RA in the above ex-
periments. However, addition of anti-TNF antibody (a-TNF+IL-
1RA) did not have any further inhibitory effect (Figure 4A,
compare IL-1RA versus a-TNF+IL-1RA). Similarly, adding anti-
TNF antibody alone failed to show a significant inhibition in the
expression of most protumor genes (Figure S3C).
We also examined whether IL-1RA treatment altered the pro-
tumor functions of RCC-conditionedmonocytes. Figures 4B and
4C show that supernatants from RCC-conditioned monocytes
that had received IL-1RA treatment displayed a significant
reduction of angiogenesis and tumor cell invasion. Similar results
were reproduced in monocytes cocultured with another
metastatic RCC cell line, A498 (Figures 4D–4F). Together, these
results clearly indicate a role for the IL-1-IL-1R pathway in pro-
moting a protumor phenotype in RCC monocytes.
Disruption of IL-1-IL-1R Signaling Alters Macrophage
Phenotype and Restricts Tumor Growth In Vivo
In order to validate our in vitro data in an in vivo system, we es-
tablished a human RCC4 xenograft model in SCIDmice (detailed
in Supplemental Experimental Procedures). The xenograft tu-
mors showed substantial infiltration of F4/80+ TAMs (constituting
>10% of the total live tumor cell population) (Figures S4A and
S4B, left panel). To trace the origin of these TAMs,we used a pre-
viously reported fate-mapping approach for labeling blood
monocytes in vivo with fluorescent latex beads that could then
be tracked in the tumors (Movahedi et al., 2010). Figure S4C
shows the infiltration of labeled inflammatory monocytesmmunity 41, 815–829, November 20, 2014 ª2014 Elsevier Inc. 819
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Figure 3. Protumor Phenotype of RCC Monocytes Is Regulated by NF-kB-MyD88 Pathway
(A) Immunoblot for phospho I-kBa (p-IkBa) expression in monocytes cocultured with RCC cells (Mo+RCC) versus monocytes cultured alone (Mo).
(B) Nuclear translocation of p65 NF-kB in Mo+RCC (see insets in merge panel).
(C) Downregulated expression of the indicated genes in Mo+RCC treated with IKKg inhibitor peptide. Data are mean ± SD representative of two independent
experiments; *p < 0.05, versus control peptide-treated Mo+RCC.
(legend continued on next page)
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Role of Monocytes and Macrophages in Human Cancer(CD11b+Ly6ChiF4/80lo) and TAMs (CD11b+Ly6Chi/loF4/80hi) in
the RCC tumors with monocyte percentage decreasing, while
TAM percentage increases from day 8 to 14 of tumor growth.
These results indicate inflammatory bloodmonocytes to infiltrate
the RCC tumors and differentiate into TAMs. Moreover, TAMs
showed protumor gene expression, as revealed by upregulation
of TNF, IL6, IL1B, PTGS2, VEGFA, and MMP10, compared to
peritoneal macrophages (PECs) from tumor-free animals (Fig-
ure S4D). Further evidence for their protumor role came from a
monocyte-macrophage depletion experiment, using liposome-
clodronate injection, which significantly reduced tumor growth
in our RCC4 xenograft model (Figure S4E).
We next investigated the involvement of IL-1-IL-1R signaling in
driving the protumor phenotype of TAMs in vivo using the above
xenograft tumor model. Initial immunohistochemistry revealed
the presence of IL-1b in the RCC4 tumor tissues (Figure S4B,
right). To directly assess the role of IL-1R signaling in driving
TAMs to adopt a protumor phenotype and support disease pro-
gression in vivo, we injected tumor-bearing animals with recom-
binant IL-1RA or PBS intratumorally on days 7, 9, and 11 after
tumor implantation (as described in Supplemental Experimental
Procedures). Tumor take was monitored throughout and TAMs
were analyzed after sacrifice on day 20-21. IL-1RA treatment
resulted in a decrease in tumor growth (Figure 5A). TAMs from
IL-1RA-treated mice showed amarked downregulation of protu-
mor genes as compared to TAMs from PBS-treated mice
(Figure 5B). In line with this, culture supernatants of TAMs from
IL-1RA-treated tumor showed lesser angiogenic activity and tu-
mor cell invasion, indicating diminished protumor functions (Fig-
ures 5C and 5D). The ability of a-VEGFR2 antibody and MMP
inhibitor to block angiogenesis and tumor cell invasion induced
by TAM supernatants mechanistically links these functions
to VEGFA and MMP10 expression by TAMs. Additionally, in vivo
imaging confirmed reduced angiogenesis andMMPactivity (= in-
vasion) in situ in the tumors of IL-1RA-treated mice (Figure 5E).
Finally, our observations were also reproduced in another RCC
xenograft model using the aggressive A498 line (Figure S5A).
Decreased tumor growth (Figure S5B) and abrogation of TAM
protumor gene expression and function were noted in the IL-
1RA-treated animals (Figures S5C–S5E). However, TAM infiltra-
tion did not show any significant change between PBS- and IL-
1RA-treated tumors in both our xenograft models (Figure S5F).
As TAMs have been considered as polarized macrophages,
we wondered whether IL-1RA could change the polarization
status of these cells. TAMs from PBS-treated, tumor-bearing
mice displayed a IL12BloIL10hi/NOS2loARG1hi gene-expression
profile, which is characteristic to murine M2 macrophages.
In contrast, TAMs from IL-1RA-treated tumor-bearing mice
showed increased IL12B and NOS2 expression accompanied
by decreased IL10 and ARG1 expression, suggestive of a skew-
ing toward the so-calledM1-like phenotypewith respect to these
markers (Figure 5F).(D) Inhibition of endothelial tube formation and (E) tumor cell invasion induced b
inhibitor or its control peptide. Data are mean ± SEM representative of two indep
(F) Downregulated expression of the indicated genes in RCC-cocultured monocy
two independent experiments; *p < 0.05 versus RCC+Mo treated with control pe
(G) Inhibition of endothelial tube formation and (H) tumor cell invasion induced by s
inhibitor. Data are mean ± SEM representative of three independent experiments
ITaken together, themultiple evidences present above demon-
strate that in vivo targeting of the IL-1-IL-1R pathway by IL-1RA
could indeed abrogate the protumor gene expression and func-
tions of TAMs resulting in decreased tumor growth.
Genetic Blockage of IL-1-IL-1R Pathway Inhibits Tumor
Growth and Protumor Phenotype of TAMs
Consistent with the above data, we also demonstrate that RCC4
xenografts display reduced growth in Il1r1/ SCID mice (Fig-
ure 6A) and that TAMs from these animals exhibit reduced
expression of protumor genes compared with their WT counter-
parts (Figure 6B). To specifically prove that the IL-1R pathway
in macrophages was essential for their tumor-promoting role,
we adoptively transferred WT or Il1r1/ macrophages into our
RCC xenograft model and assessed its impact on tumor growth
(treatment regime is described in Supplemental Experimental
Procedures). Indeed, adoptive transfer of Il1r1/ macrophages
resulted in reduced tumor growth, in vivo angiogenesis, and
MMP activity (Figures 6C and 6D), indicating that the IL-1R
pathway in macrophages was instrumental in regulating the
tumor-promoting role. These observations provide additional
support for the integral in vivo role of IL-1-IL-1R signaling in
shaping the protumor phenotype of host macrophages and in
driving RCC tumor progression.
IL-1B Expression Correlates with Cancer Stage,
Myelomonocytic, and ProtumorGeneExpression in RCC
Our mechanistic studies demonstrated a central role for the IL-
1-IL-1R pathway in polarizing monocytes-macrophages toward
a protumor phenotype and in supporting RCC progression.
We therefore investigated whether there was an association
between IL-1 expression, monocyte-macrophage profile, and
expression of protumor genes in tumor tissues obtained from
RCC patients. To this end, we performed a meta-analysis of
tumor gene-expression data from a cohort of 34 RCC patients
with a tumor node staging, available on Oncomine (Rhodes
et al., 2004; Yang et al., 2005). We observed that higher IL1B
expression in tumors significantly correlated with advanced
tumor stages (Figure 7A). Moreover, increased IL1B expression
correlated with expression of protumor genes including PTGS2
and IL6 and that of monocyte-macrophage-specific markers
like CD14, CD11b, and CD163 (Figure 7B). Accordingly, tumor
sections from RCC patients displayed substantial infiltration of
CD163+ TAMs (Figure 7C). In line with this, CD163 gene expres-
sion in the Yang et al. (2005) data set significantly correlated
with the expression of other macrophage-specific markers
(CD14, CD11b) and protumor genes (PTGS2, IL8, IL6), impli-
cating the expression of these protumor genes by TAMs
(Figure 7D).
Using another independent approach involving a gene set
enrichment analysis (GSEA), we showed a significant enrichment
(p = 0.012) of our earlier identified protumor gene panel andy supernatant from RCC-cocultured monocytes that were treated with IKKg
endent experiments; **p < 0.05 versus RCC+Mo treated with control peptide.
tes treated with MyD88 inhibitor peptide. Data are mean ± SD representative of
ptide.
upernatant fromRCC-coculturedmonocytes that has been treatedwithMyD88
; **p < 0.05 versus RCC+Mo treated with control peptide. See also Figure S2.
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Figure 4. IL-1-IL-1R Signaling Shapes the
Protumor Phenotype of RCC Monocytes
(A) Expression of the indicated genes in RCC co-
cultured monocytes (RCC+Mo) in the presence or
absence of recombinant IL-1RA (20 ng/ml) and/or
TNF blocking antibody (a-TNF, 10 mg/mL). Data
are mean ± SEM (n = 3–4); *p < 0.05, versus
Mo+RCC.
(B) Endothelial tube formation (angiogenesis
assay) and (C) tumor cell invasion induced by
supernatant from RCC+Mo that were treated with
or without recombinant IL-1RA. Data in (B) and
(C) are mean ± SEM and a representative of
three independent experiments; *p < 0.05 versus
Mo+RCC.
(D) Expression of the indicated genes in mono-
cytes that were cocultured with A498 cells
(Mo+A498) in the presence or absence of recom-
binant IL-1RA (20 ng/ml).
(E) Endothelial tube formation and (F) tumor cell
invasion induced by supernatant from Mo+A498
that were treated with or without recombinant IL-
1RA. Data in (D)–(F) are mean ± SEM from one
experiment; *p < 0.05 versus Mo+A498. See also
Figure S3.
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IL8, MMP10, CD11b, MMP10, IL1B, PTGS2, CD163, CSF1R,
CD14, and CD68) in stage IV (advanced) versus stage I (early)
tumor samples of the Yang et al. (2005) data, inferring the
presence of protumor TAMs. Confirming this protumor pheno-
type of TAMs, we demonstrated that TAMs isolated from our822 Immunity 41, 815–829, November 20, 2014 ª2014 Elsevier Inc.RCC patient tumors upregulated expres-
sion of protumor genes (TNF, IL6, IL1B,
PTGS2, VEGFA, IL8, and MMP10) (Fig-
ure 7E) and protumor functions like angio-
genesis and invasion, as compared to
macrophages from healthy donors (Fig-
ures 7F and 7G). This was consistent
with the protumor phenotype of RCC
monocytes, in vitro RCC ‘‘conditioned’’
monocytes, and TAMs in the RCC xeno-
graft model, described earlier (Figures 2,
S2, and 5).
Together, the above analysis further
supports a significant relationship be-
tween IL1B expression, TAM recruitment
and expression of protumor genes, and
malignant progression of human RCC.
Additionally, it also confirmed the pro-
tumor phenotype of TAMs in our RCC
patient tumors.
DISCUSSION
The present study reports a tumor-
promoting role for monocytes and
macrophages in human RCC and iden-
tifies a crucial contribution of IL-1-IL-1R
pathway in shaping the tumor-promotingphenotype of these cells. Monocytes from RCC patients dis-
played a distinct transcriptomal profile that was characterized
by a proinflammatory and tumor-promoting gene signature.
Proinflammatory cytokines and chemokines support cancer-
related inflammation (Hanahan and Weinberg, 2011; Mantovani
et al., 2008), while expression of molecules such as VEGFA,
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B Figure 5. IL-1-IL-1R Pathway Disruption
Modulates Tumor Progression In Vivo
(A) Kinetics of tumor growth. Data are mean ± SEM
from a representative experiment with four mice
per group. Experiment was repeated three times
independently. *p < 0.05 versus PBS-treated
group.
(B) Gene expression analysis of TAMs from PBS-
or IL-1RA-treated mice assessed by qPCR. Data
are mean ± SEM from three independent experi-
ments (total of 13–15 mice per group). *p < 0.05
versus PBS-treated group.
(C) Angiogenesis and (D) tumor invasion assay
performed with supernatants of TAMs from either
treatment groups. Data are mean ± SEM and from
one experiment with four mice per group. *p < 0.05
versus PBS-treated group.
(E) In vivo imaging of angiogenic and MMP
activity in the tumors using the Angiosense and
MMPsense dyes as described in Supplemental
Experimental Procedures. White arrow indicates
tumor site.
(F) Polarization of TAMs from PBS- or IL-1RA-
treated mice. Data are mean ± SEM from three
independent experiments (total of 13–15 mice per
group) *p < 0.05, #p < 0.05 versus expression of
the corresponding gene in PBS-treated group.
See also Figures S4 and S5.
Immunity
Role of Monocytes and Macrophages in Human CancerIL-8, COX2, and MMP10 supports key processes in tumor
development. Accordingly, enhanced gene expression of these
molecules in monocytes from RCC patients (and in RCC-condi-
tioned monocytes generated in vitro) was linked to enhanced
tumor-promoting functions, including significant increases in
angiogenic and tumor cell invasive activity. The same tumor-pro-
moting function and gene profile was mirrored in the TAMs iso-
lated from RCC patients and human (RCC) xenograft tumors.
Previous studies in mouse models of spontaneous breast and
skin cancer have identified a role for myelomonocytic cells in
mediating the ‘‘angiogenic switch,’’ malignant progression, and
metastasis (Andreu et al., 2010; Lin and Pollard, 2007; Qian
et al., 2011). However, such a role for these cells in human can-
cer needs to be demonstrated. Our studies on monocytes and
macrophages from RCC patients provide direct evidence of a
protumor role for these cells in a human cancer. In support,
epidemiological studies have previously correlated macrophage
infiltration with poor prognosis in several human cancers like
breast, cervix, prostate, gastric, and Hodgkin’s lymphoma (Bin-Immunity 41, 815–829, Ngle et al., 2002; Steidl et al., 2010; Zhang
et al., 2012). In contrast, macrophage
infiltration is associated with a good prog-
nosis in human colon cancer (Bingle et al.,
2002). These data not only highlight a
divergent role for these cells in different
types of human cancer, but also empha-
size the need to investigate their function
in each human cancer subtype. In addi-
tion, monocytes and macrophages can
adopt different strategies to support tu-
mor growth in different cancer subtypes.Besides exerting protumor activity bymodulating cancer-related
inflammation, angiogenesis, and invasion, as observed in RCC
monocytes, they can also promote tumor progression by skew-
ing and/or suppressing antitumor T cell responses via factors like
iNOS, Arginase1, B7-H1, and B7-H4. In human HCCs, B7-H1+
peritumoral monocyte-macrophages suppressed cytotoxic ac-
tivity of B7-H1 receptor-expressing CD8+ T cells (Kuang et al.,
2009). Similarly, myeloid-derived suppressor cells (MDSCs), by
expressing Arginase 1 and iNOS, mediate suppression of T cell
responses in several human cancers (Gabrilovich and Nagaraj,
2009). However, B7-H1, B7-H4, iNOS, and Arg1 failed to show
up among the significantly modulated genes in the human
RCC monocytes profiling. While our data favor direct protumor
activity of monocytes and macrophages in RCC, their relative
role in modulating tumor-induced immunosuppression needs
further study.
Although protumor activity has been generally linked to M2
polarization of macrophages, depending on the plasticity of
these cells, their spatiotemporal location, and the type of tumorovember 20, 2014 ª2014 Elsevier Inc. 823
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B Figure 6. IL-1R1 Deficiency Affects Tumor
Growth and Protumor Phenotype
(A) RCC tumor volume in WT and Il1r1/ mice at
day 15.
(B) qPCR analysis of the indicated genes in TAMs
from WT or Il1r1/ RCC tumor bearing mice.
Data in (A) and (B) are mean ± SD and from a
representative experiment with three mice per
genotype. Experiment was repeated three times
independently. *p < 0.05 versus WT.
(C) Adoptive transfer of Il1r1/ versus WT mac-
rophages (mac) were performed in the RCC
xenograft model as indicated in the Supplemental
Experimental Procedures. Thereafter, tumor
growth was assessed for these two groups of
mice. Data are mean ± SEM and from an experi-
ment with fivemice per group. *p < 0.05 versusWT
macrophages.
(D) In situ angiogenesis and MMP activity in the
tumors by in vivo imaging.
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Role of Monocytes and Macrophages in Human Cancerinvolved, diverse polarized states of macrophages (viz M1-like,
M2-like, or a mixture of both) have been implicated in tumor pro-
motion (Biswas and Mantovani, 2010; Biswas et al., 2008; Cav-
nar et al., 2013; Franklin et al., 2014; Movahedi et al., 2010).
This also supports the growing evidence that the phenotype of
these cells in vivo is more complicated than clear-cut M1 or
M2 polarized states (Murray et al., 2014). Indeed, microarray of
RCC monocytes failed to reveal a specific polarization profile
but rather showed a mixed expression of M1 and M2 genes.
Considering the in vivo plasticity of monocyte-macrophage, their
lack of clear-cut polarization phenotype in vivo, the paucity of
conserved M1 versus M2 markers (between mice and human),
and the fact that some genes can promote both M1 or M2 states
depending on their context, assessing these cells in terms of a
few M1 and M2 markers may not provide a complete picture of
their in vivo phenotype (Murray et al., 2014). Instead, defining
these cells by their function would be more relevant in such
in vivo settings. Following such a functional definition, our data
from RCC monocytes, tumor ‘‘conditioned’’ monocytes and
TAMs demonstrate a consistent protumor phenotype, charac-
terized by the upregulation of the same protumor genes, func-
tions, and mechanistic pathway, irrespective of the M1-M2
markers.
Previous reports on the role of myelomonocytic cells in tumor
progression have focused mainly on macrophages, while the
contribution of blood monocytes in cancer development has re-
mained unclear. Three recent studies in mouse mammary carci-
noma model have indicated that inflammatory monocytes are
precursors of TAMs and can contribute to tumor metastasis
and immunosuppression (Caso et al., 2010; Movahedi et al.,
2010; Qian et al., 2011). Our present findings provide transcrip-824 Immunity 41, 815–829, November 20, 2014 ª2014 Elsevier Inc.tomic and functional demonstration of
the protumor role of blood monocytes
in human cancer. Our biochemical
studies in RCC-conditioned monocytes
indicated that the expression of protumor
genes, as well as tumor-promoting func-
tions like angiogenesis and invasion, areregulated through a MyD88-dependent NF-kB pathway. These
data are in accordance with a report that used coculture of syn-
genic mouse ovarian cancer cells with bone-marrow-derived
macrophages deficient in MyD88 or IKKb to demonstrate a
key role for these signaling molecules in regulating tumor inva-
siveness (Hagemann et al., 2008). MyD88-dependent signaling
was also implicated in tumorigenesis in a mouse model of spon-
taneous ApcMin/+ intestinal cancer (Rakoff-Nahoum and Medz-
hitov, 2007). In the current report, we used both in vitro and
in vivo approaches to uncover a key role for IL-1-IL-1R, up-
stream of MyD88, in driving the ‘‘protumor’’ phenotype of
monocyte and macrophage in RCC. This is supported by
several lines of evidence. First, gene-expression data indicated
upregulation of IL1A and IL1B and its receptor IL1R1 (but not
its antagonist, IL1RN) in RCC monocytes. Second, in vitro
treatment of RCC-conditioned monocytes with IL-1RA (an
antagonist of IL-1-IL-1R1 signaling) impaired their expression
of protumor genes and protumor activity (angiogenesis and
invasion). Third, in vivo studies in a xenograft model of human
RCC demonstrated that IL-1RA injection impaired the expres-
sion of protumor genes and functions by TAMs and restricted
tumor growth, angiogenesis, and invasion (MMP activity).
Fourth, TAMs from Il1r1/ mice displayed a marked reduction
in protumor gene expression that correlated with reduced tumor
growth. Finally, adoptive transfer experiments with WT or
Il1r1/ macrophages in our RCC xenograft model proved the
specific contribution of macrophage IL-1R pathway in tumor
promotion. Together, these data support a role for IL-1-IL-1R
pathway in driving the tumor-promoting phenotype of mono-
cytes and macrophages in human RCC, thereby regulating dis-
ease progression.
Immunity
Role of Monocytes and Macrophages in Human CancerIn support of these findings, an IL-1R-MyD88 signaling
pathway was recently reported to mediate keratinocyte trans-
formation and tumorigenesis (Cataisson et al., 2012). Onco-
genic keratinocytes were shown to employ an IL-1a-IL-1R-
MyD88 autocrine loop to induce inflammation and promote
oncogenesis. In a separate transgenic mouse model, stom-
ach-specific overexpression of human IL-1b was reported to
induce spontaneous gastric inflammation-associated cancer
accompanied by the recruitment and activation of myeloid-
derived suppressor cells (MDSCs) (Tu et al., 2008). Other
studies in a murine chemical carcinogenesis model have previ-
ously demonstrated a role for IL-1b in the recruitment of myeloid
and endothelial cells, and in angiogenesis and invasive potential
of tumor cells (Carmi et al., 2009; Krelin et al., 2007). Together,
these studies indicate that the tumorigenic effect of the IL-1-IL-
1R pathway might either be intrinsic to transformed cells or
could be mediated by indirect crosstalk between transformed
cells and stromal cells (e.g., immune cells, endothelial cells,
cancer-associated fibroblasts [Erez et al., 2010]). In human
RCC, we show an IL-1/IL-1R-dependent mechanism to be
crucial in shaping the tumor-promoting phenotype of mono-
cytes and macrophages. Accordingly, increased IL-1b serum
concentrations, its positive correlation with tumor size, and
elevated IL-1b expression in tumor supernatants have been
mentioned in some RCC patient studies (van Rossum et al.,
2009; Yoshida et al., 2002). We also noted an increased IL-1b
(but not IL-1a) in the plasma of RCC patients, as compared to
healthy donors. A separate study further demonstrated that
higher IL-1b expression is associated with more malignant hu-
man RCC cell lines and correlates with increased invasive ability
(Chuang et al., 2008). Alternatively, proinflammatory cytokines
such as IL-6 and TNF-a have also been implicated in the path-
ogenesis of RCC (Balkwill, 2009; Dosquet et al., 1994; Koo
et al., 1992; Yoshida et al., 2002). However, it is worth noting
that IL-1 being a primary cytokine is known to induce and
amplify the production of both IL-6 and TNF (Granowitz et al.,
1992). Although our data suggest the IL-1-IL-1R pathway as a
crucial mediator of the protumor effects of monocytes and mac-
rophages in human RCC (and although blocking TNF-a did not
show any significant effect over IL-1RA on these cells in vitro),
we cannot exclude the simultaneous involvement of other cyto-
kine/receptor crosstalks.
By conducting a meta-analysis on tumor gene-expression
data in a cohort of 34 RCC patients (Yang et al., 2005),
we were able to demonstrate a positive correlation between tu-
mor stage and intratumoral expression of IL1B. Expression of
IL1B significantly correlated with the expression of protumor
genes (including IL6 and PTGS2) and myelomonocytic markers
(including CD14, CD11b, and CD163). Intriguingly, infiltration
of CD163+ macrophages into human RCC tissues has recently
been suggested to predict poor prognosis (Komohara et al.,
2011). In our meta-analysis, we observed that CD163 gene
expression in human RCC tumors is significantly correlated
with the expression of IL1B, IL6, and IL8, and with macrophage
markers including CD11b and CD14. GSEA analysis on this data
set also showed significant enrichment of monocyte-macro-
phage specific markers and their protumor genes preferentially
in the advanced (stage IV) tumor tissues (which correlates with
increased IL1B expression). Taken together, these observationsIprovide further evidence of a significant role for IL1B expression
in regulating TAM recruitment/transcriptional profile and in dis-
ease progression in human RCC. However, it may be pointed
out that although blood monocytes and TAMs in our study
showed a consistent protumor phenotype, divergence arising
out of their different tissue localization is expected. Studies in
mice have illustrated how different tissue microenvironments
(Gautier et al., 2012) and spatial localization within tumors can
influence monocyte and macrophage transcriptional profiles
(Movahedi et al., 2010). However, such issues are at its infancy
in the human settings. Future studies involving an in-depth,
side-by-side comparison of bloodmonocyte and TAM transcrip-
tome from the same patient (and if possible at different disease
stages) should bring to light the conserved and divergent
features of these cell types and their plasticity during human
cancer progression, thereby providing further insight for specific
targeting options.
In conclusion, the present study reports a transcriptomic
and molecular profiling of blood monocytes in human RCC,
revealing their direct role in tumor promotion. We have further
demonstrated that IL-1-IL-1R signaling critically regulates the
tumor-promoting phenotype of monocytes and macrophages
in this cancer. Based on these data, it is possible that thera-
peutic manipulation of IL-1-IL-1R signaling in human cancers
could be used to block the protumor role of monocytes
and macrophages and reprogram them to restrict cancer
progression in vivo. IL-1R antagonists such as Anakinra
(used for treating autoinflammatory diseases and arthritis) are
already available in the clinics. Hence, the potential efficacy
of anti-IL-1 therapy for selected human cancers merits further
investigation.
EXPERIMENTAL PROCEDURES
Quantitative PCR
Cells were lysed with Trizol (Life Technologies, Invitrogen) and total RNA was
prepared using the RNAeasy kit (QIAGEN) according to the manufacturer’s
instructions. Typically, 0.5 mg of total RNA was reverse transcribed and the
cDNA used for quantitative qPCR analysis on an iCycler iQ5 Real-Time PCR
detection system (BioRad) as per manufacturer’s instructions. In all cases,
target gene expression was normalized to the expression of the housekeeping
gene, B-actin. Relative gene expression was calculated using the standard
2-DDCt method.
Isolation and Culture of Human Blood Monocytes
Mononuclear cells were isolated from blood obtained from healthy volunteers
through the blood bank of Health Sciences Authority, Singapore, using Ficoll-
Hypaque Plus (Amershan Biosciences) density gradient centrifugation.
Monocyte isolation was performed using the CD14+ monocyte isolation kit
from Miltenyi Biotec (Bergisch Gladbach) according to the manufacturer’s
instruction. Isolated monocytes were cultured in IMDMmedium (IMDM-modi-
fied HyClone medium containing HEPES and 4 mM L-glutamine; Thermo
Scientific) supplemented with 5% (v/v) human serum and 100 U/ml peni-
cillin-streptomycin, and used as indicated in the Results.
RCC Patient Sample and Protocols
Peripheral blood (10–15ml) of 14 RCCpatients with early ormetastatic disease
was obtained from the National University Hospital (NUH), National University
Health System (NUHS), Singapore. Exclusion criteria at baseline included
active infection, known immunocompromised states or other active immune
conditions, and no chemotherapy or other immunomodulating treatments in
the past 6 months. None of the patients had undergone any systemic anti-
cancer therapy at the time of blood collection. Pathologically, the RCC casesmmunity 41, 815–829, November 20, 2014 ª2014 Elsevier Inc. 825
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Figure 7. Increased IL1B Expression Correlates with Cancer Stage, Expression of Monocyte andMacrophageMarkers and Protumor Genes
in RCC Patients
(A) Bar graph shows the expression of IL1B gene across different tumor stages as revealed by meta-analysis of an ONCOMINE gene expression data set from
RCC patients (n = 34), *p < 0.05 for comparisons indicated in the figure.
(B) Correlation analysis between IL1B gene expression and the expression of the indicated genes.
(C) Immunohistochemistry showing CD163+ macrophages (dark brown stained) in human RCC tumor tissue.
(legend continued on next page)
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Role of Monocytes and Macrophages in Human Cancerconsisted of 12 clear cell and 2 unclassified subtypes. Cancer staging for the
14RCCcaseswere as follows: 11 stage IV, 2 stage III, and 1 stage II. Monocyte
isolation from patient blood was done using the samemethod as described for
monocytes from healthy volunteers. The culture conditions remained the same
as described above. In addition, fresh RCC tumor tissues were also provided
for 4 RCC cases (3 clear cell and 1 chromophobe subtype; cancer staging: 2
stage I, 1 stage II, 1 stage IV) kindly by the Tissue Repository, Department
of Pathology, NUHS, Singapore. All study protocols were approved by the
DSRB Ethics Committee (NHG, Singapore) and in accordance with the
Helsinki Declaration of 2000. Informed consent was obtained from all human
subjects included in this study.
Endothelial Tube Formation or Angiogenesis Assay
Angiogenesis assay on HUVEC cells was performed. In brief, HUVEC cells (23
104/well) were seeded on matrix gel in a 24-well plate and incubated with
500 ml of cell-free supernatant (20% v/v) of monocytes from healthy donors
or RCC patients at 37C for 6–8 hr. Endothelial tube formation was accessed
and photograph was taken at a magnification of 103 using an inverted micro-
scope (Zeiss). Quantitative analysis of tube formation was done by counting
the number of tubes in at least four differentmicroscopic fields for each sample
and represented as average number of tubes per field. Generation of cell-free
monocyte supernatants used in the above assay is described in the Supple-
mental Experimental Procedures.
Tumor Cell Invasion Assay
Tumor cell invasion assay was performed using RCC cells on transwell inserts
(8 mm) coated with matrix gel Geltrex, (Invitrogen Life Technologies). Inserts
were then placed in a 24-well plate containing 500 ml cell-free supernatant
(50% v/v) from monocytes or RCC monocytes and incubated at 37C for
16 hr. After incubation, media was aspirated from the wells and inserts and
noninvaded cells on the upper side of the membrane were removed with a
cotton swab. Invaded cells attached to the bottom side of the membrane
were fixed with cold methanol, air-dried, and stained with 0.1% (v/v) crystal
violet solution. Inserts were washed and pictures were taken at a magnifica-
tion of 103 using an inverted microscope (Zeiss). Stained cells were then
lysed by 10% (v/v) acetic acid and the optical density was quantified in a plate
reader at 595 nm (TECAN Infinite M200). Generation of cell-free monocyte
supernatants used in the above assay is described in the Supplemental
Experimental Procedures.
Statistical Analysis
Statistical significance was calculated by Student’s t test when comparing two
groups or by one-way or two-way ANOVA when comparing three or more
groups. A p value < 0.05 was considered as statistically significant.
Additional methods, including reagents, cell lines, mice, microarray and
bioinformatics analysis, biochemical assays (immunoblotting, luminex assay,
ELISA), and human RCC xenograft model are provided in the Supplemental
Experimental Procedures.
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